Skip to main content
Atrás
Watch Compare

OnKure Therapeutics, Inc.

Calidad de datos: 83%
OKUR
Nasdaq Manufacturing Chemicals
$4.41
▲ $0.03 (0.57%)
Cap. Mercado: 60.23 M
Precio
$4.41
Cap. Mercado
60.23 M
Rango del Día
$4.25 — $4.46
Rango de 52 Semanas
$1.70 — $4.75
Volumen
199,711
Apertura $4.39
Promedio 50D / 200D
$3.18
38.37% above
Promedio 50D / 200D
$2.85
54.36% above

Quick Summary

Puntos Clave

Negative free cash flow of -51.87 M

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-82.32%
Below sector avg (-53.41%)
ROIC-68.56%
Net MarginN/A
Op. MarginN/A

Seguridad

Debt / Equity
N/A
Current Ratio11.45
Interest Coverage-18.34

Valoración

PE (TTM)
-1.01
Above sector avg (-1.48)
P/B Ratio0.91
EV/EBITDAN/A
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (1364 pares)
Métrica Acción Mediana del Sector
P/E -1.0 -1.5
P/B 0.9 1.6
ROE % -82.3 -53.4
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

ETFs Holding This Stock

AVSC logo AVSC Avantis U.S. Small Cap Equity ETF
0.00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -59.52 M
ROE -82.32% ROA -74.91%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -51.87 M
ROIC -68.56% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 11.45
Interest Coverage -18.34 Asset Turnover N/A
Working Capital 65.28 M Tangible Book Value 66.43 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1.01 Forward P/E N/A
P/B Ratio 0.91 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -86.12%
Market Cap 60.23 M Enterprise Value -10.10 M
Per Share
EPS (Diluted TTM) -4.40 Revenue / Share N/A
FCF / Share -3.79 OCF / Share -3.79
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 87.16%
SBC-Adj. FCF -61.31 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — 0.0 — — —
Net Income -59.52 M -52.67 M -77.39 M -51.96 M -39.77 M
EPS (Diluted) -4.40 -15.28 -2.52 -2.12 -2.19
Gross Profit — — — — —
Operating Income -62.95 M -54.39 M -83.05 M -53.85 M -39.82 M
EBITDA — — — — —
R&D Expenses 48.26 M 43.80 M 56.61 M 37.71 M 28.17 M
SG&A Expenses — — — — —
D&A 447,000.0 459,000.0 170,000.0 88,000.0 50,000.0
Interest Expense 3.43 M 1.71 M — — —
Income Tax 0.0 — 0.0 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 62.12 M 114.91 M 107.44 M 108.18 M 154.02 M
Total Liabilities 5.93 M 11.08 M 18.83 M 8.21 M 6.81 M
Shareholders' Equity 56.18 M 103.83 M 88.61 M 99.97 M 147.21 M
Total Debt — — — — —
Cash & Equivalents 59.05 M 110.76 M 27.63 M 19.93 M 124.66 M
Current Assets 60.84 M 113.00 M 106.62 M 106.35 M 153.73 M
Current Liabilities 5.92 M 10.53 M 18.18 M 7.12 M 6.20 M